Detalhe da pesquisa
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994647
2.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
3.
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
J Med Virol
; 95(2): e28452, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36597900
4.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657420
5.
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Hepatol Res
; 53(10): 960-967, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37332115
6.
Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
Hepatol Res
; 53(7): 595-606, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945790
7.
Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
J Viral Hepat
; 29(11): 976-985, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031873
8.
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
Hepatol Res
; 52(6): 508-521, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35129841
9.
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
Hepatol Res
; 52(7): 586-596, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35352445
10.
Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
Hepatol Res
; 52(7): 603-613, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35352857
11.
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
Hepatol Res
; 52(12): 1050-1059, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960789
12.
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Carcinogenesis
; 42(1): 58-69, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449510
13.
Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
J Viral Hepat
; 28(5): 755-763, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587828
14.
Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas.
Hepatol Res
; 51(8): 870-879, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894086
15.
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Hepatol Res
; 51(9): 979-989, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245216
16.
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
Hepatol Res
; 50(10): 1196-1200, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32729953
17.
High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
Hepatol Res
; 50(6): 671-681, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32020702
18.
Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
Hepatol Res
; 50(6): 715-725, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202371
19.
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Hepatol Res
; 50(8): 966-977, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32562334
20.
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
J Gastroenterol Hepatol
; 35(10): 1782-1788, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187734